Annals of Rheumatology and Autoimmunity
Refractory Lupus Panniculitis Successfully Treated with Anifrolumab: A Case Report
By Maha Alblaies, Khaled Alderaan, Mousa Alabbas and 1 others.
Abstract
Lupus panniculitis is an uncommon type of chronic cutaneous lupus erythematosus (CCLE). In cases refractory to traditional immunosuppressants, management is challenging. Anifrolumab has shown effectiveness in systemic lupus erythematosus (SLE); however, data on isolated cutaneous lupus are limited. A young female presents with painful subcutaneous nodules, diagnosed with lupus panniculitis based on skin biopsy, failed treatment with mycophenolate mofetil, hydroxychloroquine, azathioprine, and systemic corticosteroids. Anifrolumab was initiated and resulted in significant improvement without the recurrence of new lesions. We underscore the role of anifrolumab as a treatment option for refractory lupus panniculitis. However, additional studies are necessary to assess the long-term effectiveness and optimal treatment duration in CLE without SLE.
Keywords
- anifrolumab
- cutaneous lupus erythematosus
- lupus panniculitis
- type i interferon
Source
Published in Annals of Rheumatology and Autoimmunity. The abstract is shown as published and remains the work of its authors; read the full article at the source.
Prognia lists this article for reference and education. It is not medical advice. Always read the original and follow current guidelines and local protocols before acting on it.
